In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 51 days of free consultation

 

Incomplete coronary revascularization increases the risk of ventricular arrhythmias in secondary prevention implantable cardioverter defibrillator patients with coronary artery disease

Session Poster session 3

Speaker Anne-Lotte van der Lingen

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome: Risk Factors and Risk Assessment
  • Session type : Poster Session
  • FP Number : P1504

Authors : ACJ Van Der Lingen (Amsterdam,NL), MJB Kemme (Amsterdam,NL), MAJ Becker (Amsterdam,NL), AC Van Rossum (Amsterdam,NL), CP Allaart (Amsterdam,NL)

15 views

Authors:
ACJ Van Der Lingen1 , MJB Kemme1 , MAJ Becker1 , AC Van Rossum1 , CP Allaart1 , 1VU University Medical Center, Cardiology - Amsterdam - Netherlands ,

Citation:

Background: Implantable cardioverter defibrillator (ICD) implantation for secondary prevention is recommended in patients with sustained ventricular arrhythmias (VA) in absence of reversible causes. Residual myocardial ischemia might be a trigger for VA. Hence, complete coronary revascularization may be an important factor to reduce the burden of recurrent ventricular arrhythmic events.

Purpose: Aim of this study was to assess whether incomplete coronary revascularization is associated with an increase of appropriate device therapy (ADT) in secondary prevention ICD patients with coronary artery disease (CAD).

Methods: 135 consecutive patients with ischemic heart disease (89% men, age 65 ± 10 years, LVEF 38 ± 11%) who received an ICD for secondary prevention between January 2011 and June 2017 were retrospectively included. All patients experienced ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) and underwent a coronary angiogram (CAG) prior ICD implantation. CAGs were reviewed to determine if obstructive CAD was present. Incomplete revascularization was defined as =1 remaining coronary stenoses >70% in the main coronary vessels or large side-branches after ICD implantation. Coronary chronic total occlusions (CTO) who were treated conservatively were included in the incomplete revascularization group. Patients without obstructive CAD were known with a coronary stenosis <70% or received successful percutaneous coronary intervention or coronary artery bypass surgery. Clinical and laboratory variables and data about cardiac function assessed by cardiac magnetic resonance were entered in a multivariate cox regression model. ADT was defined as anti-tachycardia pacing (ATP) or shock for VT or VF.

Results: During a mean follow-up of 3.5±1.9 years, 52 (39%) patients received ADT and 17 (13%) died. Median time between CAG and ICD implantation was 15 days (IQR 0-30 days). Incomplete revascularization was found in 56 (42%) patients. Patients with incomplete revascularization received ADT more frequently compared to patients without obstructive CAD (52% vs. 29%, respectively; HR 2.05, 95% CI 1.18-3.53, p=0.01). The cumulative number of ATP or shock in patients with ADT was higher in patients with incomplete revascularization (mean number of ADT 3.8±4.0 vs. 2.1±1.2, p=0.045). A subanalysis with CTO patients (n=80) showed a trend towards more ADT in patients who were treated conservatively (HR 2.06; 95% CI 0.94–4.52; p=0.07). A multivariate analysis showed that incomplete revascularization (HR 2.2, 95% CI 1.13-3.97, p=0.02) and increased end diastolic volume (HR 1.13, 95% CI 1.01-1.26, p=0.04) were both independent predictors of ADT.

Conclusion: Secondary prevention ICD patients with CAD and incomplete revascularization are at higher risk for ADT and recurrent ventricular arrhythmic events. This study suggests that it is important to strive for complete revascularization prior to ICD implantation in patients with ischemic heart disease.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are